Neuromuscular blockade and oxygenation changes during prone positioning in COVID-19

Area of Science:

• Critical Care Medicine
• Pulmonology
• Pharmacology

Background:

• Prone positioning is a key intervention for severe COVID-19 acute respiratory distress syndrome (ARDS).
• Neuromuscular blockers (NMBs) are frequently administered during prone positioning to optimize mechanical ventilation.
• The precise impact of NMBs on oxygenation during prone therapy in COVID-19 ARDS remains incompletely understood.

Purpose of the Study:

• To investigate the effect of neuromuscular blockers (NMBs) on oxygenation in invasively ventilated adult patients with COVID-19 related ARDS undergoing prone positioning.
• To compare oxygenation levels (PaO2:FiO2 ratio) between patients receiving NMBs and those not receiving NMBs during and after prone positioning.

Main Methods:

• A multi-center observational study involving adult patients with COVID-19 ARDS requiring invasive mechanical ventilation.
• Data collection included patient demographics, prone positioning details, NMB administration, and clinical outcomes.
• Arterial blood gas parameters were analyzed during supine positioning, prone positioning, and upon return to the supine position.

Main Results:

• Patients receiving NMBs during prone positioning showed a significantly higher mean PaO2:FiO2 ratio (208 mmHg) compared to those without NMBs (161 mmHg).
• The increase in PaO2:FiO2 ratio from baseline was greater in the NMB group (76 mmHg) versus the non-NMB group (55 mmHg) during prone positioning.
• This oxygenation benefit was sustained upon return to the supine position, with higher PaO2:FiO2 ratios observed in the NMB group (190 mmHg) compared to the non-NMB group (141 mmHg).

Conclusions:

• Neuromuscular blockers are associated with improved oxygenation in COVID-19 ARDS patients undergoing prone positioning.
• The positive effect of NMBs on oxygenation persists even after patients are returned to the supine position.
• These findings support the judicious use of NMBs to enhance ventilation and oxygenation strategies in critically ill COVID-19 ARDS patients.